Search PubMed⌕ Search

Biomedical subjects

T Kumasaka

Publications and source records attributed to T Kumasaka.

At least 55 records · Page 3Linked to original sources
PubMed1994

[Expression of prolactin gene in human decidua].

UNLABELLED: This study was designed to detect the localization of prolactin gene expressing cells in the human utero-placental unit during pregnancy. METHODS: Human endometrium was obtained at hysterectomy from normally cycling women who underwent surgery for myoma uteri. Decidual and trophoblast tissues from early pregnancy were obtained by curettage from patients undergoing therapeutic abortion at 8-10 weeks of gestation. Term placenta was obtained from patients with uncomplicated deliveries at 38-40 weeks. Total RNAs of these tissues were extracted to perform Northern blot hybridization (NBH) with the radiolabelled human pituitary prolactin cDNA probe. Frozen sections of these tissues were cut and processed for in situ hybridization (ISH) with the radiolabelled RNA probe complementary for human prolactin mRNA. RESULTS: 1. By NBH, approximately a 1.3 kilobase (kb) size band was detected in the total RNA obtained from late secretory endometrium (day 26), decidua of early pregnancy and placenta of term pregnancy, and the decidua had the most significant signal. No hybridization signal was detected in the chorionic villi in early pregnancy. 2. By ISH, a significant hybridization signal was detected in the cytoplasm of the decidual cells in early and term pregnancy. No hybridization signal was detected in the endometrial grandsand trophoblast cells. CONCLUSION: These results indicate that prolactin is synthesized in the decidual cells in the human uterus during pregnancy.

Animals↗
PubMed1993

[Urethral condyloma acuminatum with severe dysplasia in a male patient detected human papillomavirus type 11: a case report].

We report a case of urethral condyloma acuminatum with severe dysplasia detected human papillomavirus (HPV) type 11. A 47-year-old male patient visited St. Luke's International Hospital complaining of tumor at the urethral meatus. One small papillary lesion was found and excised. Histopathological examination revealed condyloma acuminatum with severe dysplasia. Immunohistochemical detection for HPV antigen in the specimen of condyloma acuminatum was positive and that of severe dysplasia was negative. In an electron microscopical study, viral particles were demonstrated only in the specimen of condyloma acuminatum. Detection of HPV DNA was performed using in situ hybridization (ISH) and southern blot hybridization (SBH). HPV type 11 was found in both lesions. In conclusion, although previous studies have shown that HPV type 16/18 was especially correlated with genital severe dysplasia and carcinoma, the process of malignant transformation was suggested in the association with HPV type 11.

Condylomata Acuminata↗
PubMed1992

Possible roles of arachidonic acid and its metabolites in induction of tissue plasminogen activator (t-PA) production in human fibroblast, IMR-90 cells by proteose peptone.

Proteose peptone (p.peptone) had an ability to induce tissue plasminogen activator (t-PA) production by human embryonic lung fibroblast, IMR-90 cells. We previously demonstrated that the induction was closely related to the activation of phospholipase A2 in the cells stimulated by p.peptone. In this report, we describe the involvement of arachidonate metabolism in the induction. The induction was inhibited in a dose-dependent manner by 5,8,11,14-eicosatetraenoic acid (ETYA), an inhibitor of both cycloxygenase and lypoxygenase, and also by nordihydroguaiaretic acid (NDGA), which in low concentrations selectively inhibits lipoxygenase. However, indomethacin, a specific inhibitor of cycloxygenase, had no effect on the induction. 5-hydroxyeicosatetraenoic acid (5-HETE), which is an arachidonate metabolite derived from lipoxygenase pathway, had an inductive effect, but prostaglandin E1 (PGE1), which is a metabolite from cycloxygenase pathway, had no effect on t-PA production by the cells. These results suggest that arachidonate metabolism is involved in the induction of t-PA production in IMR-90 cells by p.peptone, and that arachidonate metabolite(s) from lipoxygenase pathway is responsible for the induction.

Alprostadil↗
PubMed1992

[Hodgkin's disease associated with Behçet's disease].

This paper reports a rare case of Hodgkin's disease with Sjögren syndrome in the course of Behçet's disease. A 43-year-old man developed arthralgia of bilateral knees, ankles, elbows and wrists in May, 1988. He had hazy vision and was diagnosed as having iridocyclitis and chorioretinitis in February, 1989. Gingival ulcer, penile ulcer, erythema nodosum on the right lower leg and superficial thrombophlebitis on the bilateral arms appeared in June, 1989. Therefore, he was diagnosed as Behçet's disease. He responded well to prednisolone. In November, 1989, he developed fever with positive CRP and elevated alkaline phosphatase. Multiple mass lesions in the liver and spleen with retrocrural lymphadenopathy were noticed on the abdominal CT and echogram. A cervical lymph node biopsy revealed Hodgkin's disease of the mixed cellularity type. At the same time, the patient had dry eyes and a dry mouth. Salivary gland biopsy revealed chronic sialoadenitis with lymphocytic infiltration compatible with Sjögren syndrome. The patient responded well to ABVD regimen. He is still free of disease as of May, 1991.

Adult↗
PubMed1991

Participation of phospholipase A2 in induction of tissue plasminogen activator (t-PA) production by human fibroblast, IMR-90 cells, stimulated by proteose peptone.

Proteose peptone (p.peptone) had an ability to induce tissue plasminogen activator(t-PA) production by human embryonic lung fibroblast, IMR-90 cells. The induction was dependent on extracellular Ca2+ concentration. The stimulation of p.peptone caused uptake of 45Ca2+ by the cells. The presences of both p.peptone and Ca2+ in medium were necessary for the continuous induction of t-PA production. Hydrocortisone and dexamethasone inhibited t-PA production induced by p.peptone. In addition, the inhibitors of phospholipase A2, quinacrine and 4-bromophenacylbromide, respectively inhibited t-PA production as well as glucocorticoids. Conversely, melittin, an activator of phospholipase A2, induced t-PA production in a dose-dependent manner. Exogenous phospholipase A2 strongly induced t-PA production and also arachidonic acid moderately did in a dose-dependent manner. P.peptone stimulated the release of radioactive arachidonic acid from 3H-arachidonic acid-labeled IMR-90 cells under the presence of Ca2+. These results suggest that the induction of t-PA production by p.peptone is closely related to the activity of phospholipase A2, that is, the release of arachidonic acid from phospholipids in cell membrane.

Arachidonic Acid↗
PubMed1991

[Contractile responsiveness of the isolated guinea pig oviduct to autacoids at different phases of the sexual cycle or under ovarian steroid treatment].

Contraction of the longitudinal smooth muscle of the isolated guinea pig oviduct in response to autacoids was examined at different phases of the sex cycle or during ovarian steroid treatments. Isolated strips from isthmic smooth muscle of the female guinea pig (body weight; 300-900 g) oviduct were mounted in an organ bath and their isotonic responses were measured in the longitudinal direction. Histamine (greater than or equal to 3 X 10(-8) M) produced a concentration-dependent contraction of the oviductal smooth muscle, which was unaffected by the sex cycle. Noradrenaline and adrenaline (greater than or equal to 10(-8) M) produced a contraction mediated by alpha-adrenoceptors and a relaxation mediated by beta-adrenoceptor. During proestrus and metestrus (high estrogen), the contractile response was reduced but relaxation was increased, compared with those observed during diestrus. Prostaglandin E2 and F2 alpha (greater than or equal to 10(-10)M and greater than or equal to 10(-9)M, respectively) produced a concentration-dependent contraction and their maximum responses were about 50% of that induced by histamine (10(-4)M). These contractile responses were unaffected by the sex cycle. On the other hand, acetylcholine did not modify the smooth muscle tone of the isolated guinea pig oviduct in the concentration range from 10(-7)M to 3 X 10(-4)M. The contractile response of the oviductal smooth muscle to adrenaline after bilateral ovariectomy was inhibited by estrogen treatment, while relaxation was inhibited by progesterone treatment.

Animals↗
PubMed1990

[Digital plethysmogram in women with climacteric disturbance after cold-water challenge test and effect of estrogen].

Immediately after a cold-water challenge test (C-W test) the pulse height to the digital plethysmogram descended (descent wave: D wave), and a congestion wave (C wave) occurred after the D wave. Then the recovery wave (R wave) continued after the C wave. The effects of estrogen on the digital plethysmogram under the C-W test are as follows. (1) The D wave was less than 25% in young women and women without climacteric disturbance. (2) The recovery rate of the C wave in young women was better than in climacteric women without climacteric disturbance. (3) The before value for A1B'1/B'1C1 in the C-W test of young women was 1.0, and the other values during the C-W test did not change significantly compared with the before values. (4) U-time rose only temporarily in the former case. In addition the recovery rate of the R wave after the administration of premarin in women with climacteric disturbance was 19.3%, and this was a significant improvement over the cases without administration. The recovery rate of the R wave in the same women after the administration of premarin and cercine increased to 48.3% (p less than 0.01). These data suggested that estrogen may be able to control the function of the autonomic nervous system in climacteric woman.

Adolescent↗
PubMed1989

[Successful treatment of endometriosis in women with continuous subcutaneous infusion of gonadotropin-releasing hormone agonist (GnRH-A)].

The clinical and hormonal effectiveness of continuous infusion of GnRH-agonist (A) for the treatment of endometriosis was investigated. Five women with endometriosis (stage II-IV) were treated with continuous subcutaneous infusion of 200 micrograms of GnRH-A (Buserelin) per day for 24 weeks. Serum LH and FSH levels increased initially and then FSH levels declined markedly below pretreatment values within a week, followed by a gradual decrease to the normal range of LH levels within 4 weeks. Serum estradiol decreased below early follicular phase levels within 1 to 3 weeks and thereafter continued to decrease to near castrate levels. The LH and FSH responses to 100 micrograms GnRH challenge test were almost completely abolished within 2 weeks. The pulsatile secretion of LH and FSH were also abolished, when assessed at 16 weeks. The tendency toward the slight but significant elevation in FSH levels without an increase in estradiol was noted from about 12 weeks. No vaginal bleeding or spotting was observed in four of the five patients during the course of the treatment. After completion of the 24 weeks of treatment, FSH increased rapidly to the early follicular phase range, and ovulation returned within 4 weeks. Two of the five patients became pregnant during cycles 2 and 5. From these results, we conclude that continuous sc infusion of GnRH-A is highly effective for complete suppression of the pituitary-ovarian function in patients with endometriosis. Further, this treatment appears to be safe and acceptable, because of its rapid reversibility and its lack of side effects.

Adult↗
PubMed1989

[Continuous subcutaneous infusion of GnRH agonist: effective dosage in the treatment of endometriosis and its influence on the ovarian response to human menopausal gonadotropin].

This study was designed to compare the clinical and hormonal efficacy of the treatment for endometriosis using continuous infusion of three different doses of GnRH agonist (A). In addition, we examined the ovarian responsiveness to human menopausal gonadotropin (hMG) administration during GnRH-A treatment. Thirteen endometriosis patients were divided into 3 groups and given different doses. GnRH-A (Buserelin) was infused continuously through the subcutaneous route at rates of 200 micrograms (Group I; n = 5), 100 micrograms (Group II, n = 4) and 10 micrograms (Group III; n = 4) per day for 24 weeks. After the start of treatment, serum estradiol (E2) was suppressed to the menopausal range within 2 weeks and thereafter maintained this range until 24 weeks in each group. The LH and FSH response to a GnRH Challenge test was completely abolished within 2 weeks in 3 groups. Although serum FSH decreased to below the pretreatment value within a week, the FSH level was significantly lower in groups I and II than in group III until 8 weeks. No difference in the LH level during the treatment was seen among the 3 groups. After completion of the 24 weeks' treatment, FSH increased rapidly, and ovulation returned within 4 to 6 weeks in each group. Pregnancy was achieved in two patients in group I, one patient in group II and one patient in group III during cycles 2 and 5. Serum E2 increased to 200-300 pg/ml in 3 out of 7 patients treated with hMG during GnRH-A infusion, whereas no increase in E2 was seen in the remaining 4 patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed1988

Pulsatile secretion of prolactin and luteinizing hormone and their synchronous relationship during the human menstrual cycle.

Recent investigations have demonstrated the pulsatile nature of prolactin (PRL) secretion and the synchronous relationship between PRL and LH pulses in normal and hypogonadal women. The present study was designed to confirm this synchrony and to investigate the characteristics of PRL pulses at different stages of the menstrual cycle. Blood samples were obtained at 10-minute intervals, beginning at 10.00 hours, for a duration of 4-7 hours, from women during the follicular (n = 11), preovulatory (n = 2) and luteal (n = 10) phases. Detectable pulses in plasma PRL concentrations were present in almost all subjects during each phase of the cycle. During the total 121-hour blood sampling throughout the 3 phases, 62 PRL pulses and 74 LH pulses were detected and about 80% of the PRL pulses were observed to coincide with LH pulses. The mean (+/- SD) pulse frequency of PRL was significantly lower during the luteal phase (0.28 +/- 0.17 pulses/hour) than during the follicular (0.64 +/- 0.25 pulses/hour) and preovulatory (0.72 +/- 0.16 pulses/hour) phases, while the mean pulse amplitude of PRL was significantly greater during the luteal phase (6.8 +/- 2.3 ng/ml) than during the follicular (3.6 +/- 1.2 ng/ml) and preovulatory (4.1 +/- 1.0 ng/ml) phases. These changes in pulse frequency and amplitude were also observed in LH pulses between the follicular and luteal phases, except at the LH surge, when LH pulse amplitude increased markedly, but that of PRL did not alter. Furthermore, a positive linear correlation between the pulse frequency of PRL and LH (r = 0.74, p less than 0.001) was found throughout the 3 phases of the cycle. These results demonstrate that a marked degree of synchrony between PRL and LH pulses is observed during the menstrual cycle and suggest that the frequency and amplitude of PRL pulses vary from the follicular to luteal phases, except at the LH surge, almost in parallel with those of LH pulses.

Adult↗
PubMed1988

[Pulsatile secretion of prolactin during the human menstrual cycle].

Recent investigations have demonstrated the pulsatile nature of prolactin (PRL) secretion and the synchronous relationship between PRL and LH pulses in normal and hypogonadal women. The present study was designed to confirm this synchrony and to investigate the characteristics of PRL pulses at different stages of the menstrual cycle. Blood samples were obtained at 10-min intervals beginning at 1000 h for a duration of 4-7 h in women during the follicular (n = 11), preovulatory LH surge (n = 2) and luteal phases (n = 10). Detectable pulses in plasma PRL concentrations were present in almost all subjects during the each phase of the cycle. During the total 121 h-blood sampling throughout the three phases, 62 PRL pulses and 74 LH pulses were detected and about 80% of these PRL pulses were observed to coincide with LH pulses. The mean (+/- SD) pulse frequency of PRL was significantly lower during the luteal phase (0.28 +/- 0.17 pulses/h) than during the follicular (0.64 +/- 0.25 pulses/h) and preovulatory phases (0.72 +/- 0.16 pulses/h). The mean pulse amplitude of PRL was significantly greater during the luteal phase (6.8 +/- 2.3 ng/ml) than during the follicular (3.6 +/- 1.2 ng/ml) and preovulatory phases (4.8 +/- 1.4 ng/ml). These changes in pulse frequency and amplitude were also observed in LH pulses between the follicular and luteal phases, except during the LH surge when LH pulse amplitude increased markedly, whereas that of PRL did not alter. Further, a positive linear correlation between the pulse frequency of PRL and LH (r = 0.74; p less than 0.001) was found throughout the three phases of the cycle.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed1987

[Indication and effect of bromocriptine in euprolactinemic amenorrhea--comparison with clomiphene].

Effect of bromocriptine on induction of ovulation and occurrence of pregnancy was examined in patients with normoprolactinemic ovulatory disturbances. The patients under study (53 in number) were divided into two groups, A and B, depending on the effect clomiphene had on the ovulatory responses and the occurrence of pregnancy. Of the group A, patients (21 in number), who had failed to show any ovulatory response to clomiphene, 8 patients ovulated on bromocriptine alone. Three out of 13 patients who complained of sterility became pregnant. Three out of 8 patients who had not ovulated on bromocriptine therapy alone ovulated on a combination of bromocriptine and clomiphene, and 2 out of these 3 cases became pregnant. Of the group B patients (31 in number), who had failed to become pregnant in spite of ovulatory responses to previous clomiphene therapies, 7 out of 23 became pregnant, who complained of sterility when on bromocriptine alone. Out of 12 cases who had failed to get pregnant on the bromocriptine alone, 2 patients became pregnant on the combination of bromocriptine and clomiphene. These data may indicate that the bromocriptine or the combined therapy of bromocriptine and clomiphene is useful for the treatment of patients with ovulatory disturbances or sterility who do not respond to the clomiphene therapy.

Adult↗
PubMed1987

[Immunohistochemical localization of estradiol in malignant epithelial tumors of the ovary].

Granulosa cell tumors derived from sexcord-stromal cells are thought to be generally estrogen producing neoplasms. However recent reports show that these common epithelial tumors, adenocarcinomas and Brenner tumors, are capable of estrogen activity. We have studied the production of estrogen in common epithelial malignant tumors of the ovary. Two cases of serous cystadeno-carcinomas, five cases of mucinous cystadeno-carcinomas and two cases of endometrioid carcinomas were examined for the presence of estradiol using an indirect immunoperoxidase method. The results were as follows: In all tumors, one case of serous cystadeno-carcinoma, four cases of mucinous cystadeno-carcinomas and one case of endometrioid carcinoma had a positive immunoperoxidase reaction. The incidence of positive reaction showed that mucinous cystadeno-carcinomas were more numerous than others. In positive cases, estradiol localization was recognized in the epithelial cell of mucinous tumors to various degrees, but there was no estradiol localization in admixed goblet like cells. In serous tumors and endometrioid carcinomas also estradiol localization was seen in the cytoplasm. Stromal cells tended to be more weakly positive than epithelial cells. No estradiol localization was detected in any of the spindle cells or fibrinous connective tissues. These results suggest that some common epithelial malignant tumors of the ovary have estrogen activity and estradiol is produced not only in stromal cells but also in epithelial cells.

Adenocarcinoma↗
PubMed1986

Neuroendocrine regulation of LHRH and gonadotropin.

Analysis of gonadotropin secretion patterns throughout the menstrual cycle revealed a complex rhythm. Especially at 1-3 hour intervals this was seen, with a frequency that was dependent on the phase of the menstrual cycle. There is little information available concerning the role of plasma luteinizing hormone-releasing hormone (LHRH) in the regulation of donadotropin secretion in amenorrheic and postmenopausal women. In this paper, the authors present the results of a detailed investigation into the secretory pattern of LH, follicle stimulating hormone, and LHRH in normal women with a normal menstrual cycle, amenorrheic women, and postmenopausal women.

Amenorrhea↗
PubMed1986

[Endocrine evaluation of induction of ovulation with pulsatile and continuous administration of human menopausal gonadotropin (hMG) in anovulatory women].

To evaluate the endocrine profiles during induction of ovulation with pulsatile and continuous administration of hMG (Pergonal), 3 patients with polycystic ovarian disease (PCO) and 4 patients with hypothalamic amenorrhea were selected as the subjects. The total dose of hMG per day was 150 IU in each patient. hMG pulse was administered intravenously via a portable infusion pump every 90 min in 4 patients including 3 PCO cases (9.375 IU/pulse) and every 18 min in one patient (1.875 IU/pulse). The remaining 2 patients received continuous subcutaneous infusion of hMG (150 IU/day). Following hMG treatment, 8,000 to 10,000 IU of hCG was used to induce ovulation. All 7 patients ovulated and 4 of them conceived. Pregnancy resulted in 2 patients following pulsatile (every 90 min) administration and in 2 patients after continuous infusion. The duration of hMG treatment needed to induce ovulation was similar among the three modes of administration and within the range of 7 to 10 days. A sustained elevation of circulating FSH levels was observed in all patients and serum estradiol increased more than 3,000 pg/ml in 6 of 7 patients during the course of treatment. Mean (+/- SE) midluteal progesterone level was 107.1 +/- 20.9 ng/ml. Moderate to severe ovarian hyperstimulation occurred in all patients. These results indicate that both pulsatile and continuous administration of hMG are similarly effective in inducing ovulation. They also appear to indicate that the hMG-induced follicular development is profoundly affected by the maintenance of high levels of FSH in the circulation rather than by the mode of administering hMG, whether pulsatile or continuous.

Amenorrhea↗